文献速递乳腺癌支持与姑息治疗

乳腺癌化疗幸存者与年龄匹配对照的认知主诉:一项全国性多中心前瞻性纵向研究分析

Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
PubMed 文献 · J Clin Oncol · 2016-12-28

这项全国性多中心前瞻性纵向研究对比了581例乳腺癌化疗患者与364例年龄匹配非癌对照的FACT-Cog评分。患者从化疗前到化疗后及6个月随访时报告的认知困难均显著高于对照(所有P<.001)。患者自报临床显著认知下降的比例也高于对照(化疗前至化疗后45.2% vs 10.4%;化疗前至6个月随访36.5% vs 13.6%)。

要点

  • 乳腺癌患者化疗后及6个月随访时FACT-Cog总分及四个子量表评分均显著差于年龄匹配对照(所有P<.001)。
  • 患者自报临床显著认知下降比例化疗前至化疗后为45.2% vs 对照10.4%,至6个月随访为36.5% vs 13.6%。
  • 基线焦虑、抑郁增加和认知储备降低与较低的FACT-Cog总分显著相关。

核心结论

  • 在社区肿瘤诊所接受化疗的乳腺癌患者,至化疗结束后6个月时报告的认知困难显著多于年龄匹配的非癌对照。

研究设计与样本

  • 全国性、多中心、前瞻性纵向研究,纳入社区肿瘤诊所的乳腺癌患者和年龄匹配的非癌对照。
  • 患者在化疗前、化疗后和6个月随访时完成癌症治疗功能评估-认知功能(FACT-Cog)问卷,作为预先设定的探索性目标。
  • 共评估581例乳腺癌患者(平均年龄53岁;48%接受蒽环类为基础方案)和364例对照(平均年龄53岁)。
  • 纵向模型比较三个评估时点患者与对照的FACT-Cog评分,并校正年龄、教育、种族、绝经状态及基线阅读能力、焦虑和抑郁症状。
  • 采用最小临床重要差异截断值确定随时间变化的受损百分比。

主要发现

  • 从化疗前到化疗后以及从化疗前到6个月随访,患者FACT-Cog总分及四个子量表报告的认知困难均显著大于对照(所有P<.001)。
  • 基线焦虑增加、抑郁增加和认知储备降低与较低的FACT-Cog总分显著相关。
  • 在患者中,从化疗后到6个月随访,治疗方案、激素治疗或放疗与FACT-Cog总分无显著相关。
  • 从化疗前到化疗后,患者自报临床显著认知功能下降的比例高于对照(45.2% vs 10.4%)。
  • 从化疗前到6个月随访,患者自报临床显著认知功能下降的比例高于对照(36.5% vs 13.6%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Cancer-related cognitive impairment is an important problem for patients with breast cancer, yet its trajectory is not fully understood. Some previous cancer-related cognitive impairment research is limited by heterogeneous populations, small samples, lack of prechemotherapy and longitudinal assessments, use of normative data, and lack of generalizability. We addressed these limitations in a large prospective, longitudinal, nationwide study. Patients and Methods Patients with breast cancer from community oncology clinics and age-matched noncancer controls completed the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) at prechemotherapy and postchemotherapy and at a 6-month follow-up as an a priori exploratory aim. Longitudinal models compared FACT-Cog scores between patients and controls at the three assessments and adjusted for age, education, race, menopausal status, and baseline reading ability, anxiety, and depressive symptoms. A minimal clinically important difference cutoff determined percentages of impairment over time. Results Of patients, 581 patients with breast cancer (mean age, 53 years; 48% anthracycline-based regimens) and 364 controls (mean age, 53 years) were assessed. Patients reported significantly greater cognitive difficulties on the FACT-Cog total score and four subscales from prechemotherapy to postchemotherapy compared with controls as well as from prechemotherapy to 6-month follow-up (all P < .001). Increased baseline anxiety, depression, and decreased cognitive reserve were significantly associated with lower FACT-Cog total scores. Treatment regimen, hormone, or radiation therapy was not significantly associated with FACT-Cog total scores in patients from postchemotherapy to 6-month follow-up. Patients were more likely to report a clinically significant decline in self-reported cognitive function than were controls from prechemotherapy to postchemotherapy (45.2% v 10.4%) and from prechemotherapy to 6-month follow-up (36.5% v 13.6%). Conclusion Patients with breast cancer who were treated in community oncology clinics report substantially more cognitive difficulties up to 6 months after treatment with chemotherapy than do age-matched noncancer controls.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol. 2016. PMID: 28029304. doi:10.1200/JCO.2016.68.5826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。